Change in UCB's Executive Committee | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Change in UCB's Executive Committee

Melanie Lee, Executive Vice President UCB,
President UCB NewMedicines will leave UCB at the end of August 2009

Brussels (Belgium), 20 May 2009 - press release regulated information - UCB announced today, that Dr. Melanie Lee, Executive Vice President UCB and President UCB NewMedicines will leave UCB at the end of August 2009 and pursue other interests. Upon her departure from UCB, Melanie Lee will join the Scientific Advisory Board of UCB.

"I want to thank Melanie Lee for her strong contribution to the growth of UCB and before that, Celltech. In 2008, Melanie and her team put in place the foundations of an innovative organization named UCB NewMedicines, UCB's discovery research through to 'proof of concept' organization. We are all committed to make this new organization a leading edge discovery engine," Roch Doliveux, CEO UCB, said.

Melanie Lee has led both the discovery and research and development organizations. She has served for six years as a Board Director with Celltech and five years on UCB's Executive Committee, and has worked tirelessly through four integrations.
In 2008, she put in place the structure for a new research organization - UCB NewMedicines - designed to maximize internal and external skills and technologies from discovery research through 'proof of concept'.

UCB has initiated an external search for a new individual to lead UCB NewMedicines. The new President UCB NewMedicines will move this organization beyond its current achievements to deliver UCB's breakthrough phase.


For further information
Antje Witte, Corporate Communications & Investor Relations, UCB
T +32.2.559.9414,

Nancy Nackaerts, External Communications, UCB
M: +32 473 86 44 14,


Notes to Editors:


About UCB
UCB, Brussels, Belgium (  is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 10 000 people in over 40 countries, UCB generated revenue of EUR 3.6 billion in 2008. UCB is listed on Euronext Brussels (symbol: UCB).


Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

Asset Download

Stay up-to-date on the latest news and information from UCB